Raise Investment in Pharma R&D, Find Cure for Substandard Drugs: Glenmark India Biz Head

Learning lessons from Covid, the pharmaceutical industry is expecting policy measures to increase investments in research and development, Glenmark Pharmaceuticals India’s business head told News18.com. Alok Malik, executive vice president and business head, India formulations, told News18.com that “the industry-friendly measures will boost the on-ground execution of the government’s vision of discovering India through pharma innovation.” “As one industry, we are looking forward to having policy measures for strengthening public-private partnerships even more and increased investment in pharma research and development,” he said in the exclusive interaction. “The year 2022 saw a transformational journey for the pharma industry from being a volume creator to a value provider, as the world opened up to normal functioning post the Covid-19 pandemic,” he said. ‘Aim to be in top 10’ Glenmark aims to “outperform India’s pharmaceutical market” while maintaining a leadership position across its focused therapy categories of dermatology, respiratory, cardiovascular, oncology, and diabetes, Malik said. “While the year 2021 focused on Covid-19 therapies, in the year 2022 Glenmark’s focus extended to other therapies including diabetes, hypertension, dermatology, auto-immune and cancer,” he said.